Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
8617
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Indianapolis, Indiana. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 853–864 of 8,617 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 2 Interventional

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07024693
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions
DT-168
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Completed Phase 3 Interventional

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

NCT06846515
View directory record Official record
Conditions
Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions
AR882 50 mg, AR882 75 mg, Placebo
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Understanding and Predicting Breast Cancer Events After Treatment

NCT02791581
View directory record Official record
Conditions
Breast Cancer
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2032
U.S. locations
66
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Terminated Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

NCT03833167
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Mobile, Alabama • Duarte, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Recruiting Phase 3 Interventional

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
45
States / cities
Lancaster, California • Palm Springs, California • Pomona, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Active, not recruiting Phase 3 Interventional

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Enrolling by invitation Phase 2 Interventional

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
GT005
Genetic
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Completed Phase 3 Interventional

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

NCT06347133
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Recruiting Phase 3 Interventional

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Recruiting Phase 4 Interventional

National Liver Cancer Screening Trial

NCT06084234
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Interventions
GALAD, Liver Ultrasound with or without AFP
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
19
States / cities
Los Angeles, California • Redwood City, California • Roseville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:54 PM EST
Completed Phase 2 Interventional

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

NCT06785012
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-89495120, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:54 PM EST